COX15: A Promising Drug Target and Biomarker for Chronic Pain Management

Target Name: COX15

NCBI ID: G1355

COX15

COX15: A Promising Drug Target and Biomarker for Chronic Pain Management

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with over 90% of those occurring in low- and middle-income countries . Chronic pain can be caused by various conditions, including fibromyalgia, rheumatoid arthritis, neuropathic pain, and cancer-related pain. These conditions can significantly impact an individual's quality of life, making them prominent drug targets for therapeutic development.

COX15, a novel protein that belongs to the COX family, is a potential drug target and biomarker for the management of chronic pain. COX15 is a key mediator of pain signaling in the central nervous system and has been implicated in the development and maintenance of chronic pain. pain. Several studies have suggested that inhibiting COX15 may provide a novel and effective approach to treat chronic pain.

The COX15 Protein

COX15 is a 21-kDa protein that is expressed in various tissues and cells, including the central nervous system, peripheral nervous system, and immune cells. It is a member of the COX family, which includes other well-known proteins such as COX- 2 and COX-3. The COX15 gene has four open reading frames (ORFs), including an ORF1, ORF2, ORF3, and ORF4. ORF1 and ORF2 contain the COX15 protein-specific amino acids, while ORF3 and ORF4 encode non-protein coding regions.

COX15 is involved in pain signaling by participating in the production of pro-inflammatory cytokines, such as TNF-伪, IL-1尾, and IL-6. It also plays a role in the production of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF), which is involved in the maintenance of neural stem/progenitor cells. In addition, COX15 has been shown to promote the production of pain-related cytokines, such as IL-18, which may contribute to the persistent pain associated with chronic conditions.

The Potential of COX15 as a Drug Target

In view of the significant impact of COX15 on pain signaling, several studies have investigated the potential of inhibiting COX15 as a treatment for chronic pain. These studies have led to the development of several COX15 inhibitors that have been shown to be effective in animal models of chronic pain, including:

1. COX15 inhibitors for cancer pain: Several studies have shown that COX15 inhibitors can effectively reduce the pain caused by cancer-related pain. For example, a COX15 inhibitor, celecoxib, has been shown to significantly reduce the pain caused by human colorectal cancer- associated pain in animal models.
2. COX15 inhibitors for neuropathic pain: Neuropathic pain is a type of chronic pain that is caused by damage to the nervous system. COX15 inhibitors have been shown to be effective in reducing neuropathic pain in animal models. For instance, a COX15 inhibitor, apicachin , has been shown to effectively alleviate pain in rat models of neuropathic pain.
3. COX15 inhibitors for rheumatoid arthritis: Rheumatoid arthritis (RA) is a chronic autoimmune disorder that causes joint inflammation and pain. COX15 inhibitors have been shown to be effective in reducing joint pain and inflammation in animal models of RA. For example, a COX15 Inhibitor, etanercept, has been shown to effectively alleviate joint pain and inflammation in rat models of RA.

In addition to its potential as

Protein Name: Cytochrome C Oxidase Assembly Homolog COX15

Functions: May be involved in the biosynthesis of heme A

The "COX15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about COX15 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets